Caution should be taken with Verzenios EU/1/18/1307/010, Eli Lilly and Company Limited, Lilly dose should be reduced to 100mg bd. In patients with dose reduced to 100mg should be avoided. If strong CYP3A4 inhibitors cannot be avoided, Verzenios dose is primarily metabolised by CYP3A4, CYP3A4 inhibitors: Co-administration of 0.1/10: Infections, neutropenia, leukopenia, anaemia, thrombocytopenia, decreased appetite, dysgeusia, dizziness, diarrhoea, vomiting, nausea, alopecia, pruritus, rash, fatigue, pyrexia, increased ALT & AST. Common (1/100 to <1/10): Lymphopenia, lactic acidosis increased, venous thromboembolism (venous thromboembolic events include DVT, pulmonary embolism, cerebral venous sinus thrombosis, subdural, axillary vein thrombosis, DVT inferior vena cava and pelvic venous thrombosis). ILD/pneumonitis, dry skin, muscular weakness. Less frequent than Uncommon (<1/100): Fatial events occurred in <1% patients where neutropania or lung infection was reported. For full details of these and other side-effects, please see the Summary of Product Characteristics, which is available at Unitid Kingdom: http://www.medicines.org.uk/EMC/. Legal Category: POM. Marketing Authorisation Numbers (or Product Licence Numbers) and Holder EU/1/18/1307/010, EU/1/18/1307/011, EU/1/18/1307/012, EU/1/18/1307/013, EU/1/18/1307/014, EU/1/18/1307/015. Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands. Cost (UK only) £1475.00 per pack of 28 x 50mg film-coated tablets, £1475.00 per pack of 28 x 150mg film-coated tablets, £2950.00 per pack of 56 x 50mg film-coated tablets, £2950.00 per pack of 56 x 150mg film-coated tablets. An Irish price is available on request; please see section below for Eli Lilly and Company Ireland contact information. Date of Preparation or Last Review January 2020 Further Information is Available From: Eli Lilly and Company Limited, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL. Telephone: UK: +54 (0) 1256 315000, +353 (0) 1 681 4377, E-mail: ukmedinfo@lilly.com, Website: www.lilly.co.uk; www.lilly.ie.

Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie.